Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis

American Journal of Gastroenterology

Volumn 103, Issue 12, 2008, Pages 3094-3105

  Yen, Eugene F ^a   Kane, Sunanda V ^b   Ladabaum, Uri ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISONE; SALAZOSULFAPYRIDINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COLON RESECTION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG DOSE ESCALATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; MAINTENANCE THERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REMISSION; RISK ASSESSMENT; RISK REDUCTION; ULCERATIVE COLITIS; COST BENEFIT ANALYSIS; ECONOMICS; PROBABILITY; STATISTICAL MODEL; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COST-BENEFIT ANALYSIS; HUMANS; MARKOV CHAINS; MESALAMINE; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 58149393180     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.02130.x     Document Type: Article

References (49)

1. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003 : CD000543.
2. Sutherland L, Roth D, Beck P, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2002 : CD000544.
3. Azad Khan AK, Howes DT, Piris J, et al. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 1980 21 : 232 40.
4. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004 99 : 1371 85.
5. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial. Am J Gastroenterol 2005 100 : 2478 85.
6. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987 317 : 1625 9.
7. The Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Ann Intern Med 1996 124 : 204 11.
8. Hawkey CJ, Dube LM, Rountree LV, et al., for The European Zileuton Study Group For Ulcerative Colitis. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. Gastroenterology 1997 112 : 718 24.
9. Miner P, Hanauer S, Robinson M, et al., for the Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci 1995 40 : 296 304.
10. Sandberg-Gertzen H, Jarnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology 1986 90 : 1024 30.
11. Wright JP, O'Keefe EA, Cuming L, et al. Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig Dis Sci 1993 38 : 1837 42.
12. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006 131 : 719 28.
13. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007 132 : 507 15.
14. Hanauer S, Schwartz J, Robinson M, et al., for the Pentasa Study Group. Mesalamine capsules for treatment of active ulcerative colitis: Results of a controlled trial. Am J Gastroenterol 1993 88 : 1188 97.
15. Sutherland L, Robinson M, Onstad G, et al. A double-blind, placebo-controlled, multicentre study of the efficacy and safety of 5-aminosalicyclic acid tablets in the treatment of ulcerative colitis. Can J Gastroenterol 1990 4 : 463 7.
16. Zinberg J, Molinas S, Das KM. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. Am J Gastroenterol 1990 85 : 562 6.
17. Baron JH, Connell AM, Kanaghinis TG, et al. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. BMJ 1962 5302 : 441 3.
18. Faubion WA Jr., Loftus EV Jr., Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology 2001 121 : 255 60.
19. Hanauer S. Medical therapy for ulcerative colitis. In : Sartor RB, Sandborn WJ, eds. Kirsner's inflammatory bowel disease, 6th Ed. New York, NY : Saunders, 2004 : 503 30.
20. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001 120 : 1323 9.
21. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985 89 : 1005 13.
22. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994 330 : 1841 5.
23. Loftus CG, Egan LJ, Sandborn WJ. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am 2004 33 : 141 69, vii.
24. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003 125 : 1025 31.
25. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353 : 2462 76.
26. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992 305 : 20 2.
27. Rosenberg JL, Wall AJ, Levin B, et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975 69 : 96 9.
28. Fazio VW, Tekkis PP, Remzi F, et al. Quantification of risk for pouch failure after ileal pouch anal anastomosis surgery. Ann Surg 2003 238 : 605 14 discussion 614-7.
29. Hahnloser D, Pemberton JH, Wolff BG, et al. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Br J Surg 2007 94 : 333 40.
30. MacLean AR, Cohen Z, MacRae HM, et al. Risk of small bowel obstruction after the ileal pouch-anal anastomosis. Ann Surg 2002 235 : 200 6.
31. MacRae HM, McLeod RS, Cohen Z, et al. Risk factors for pelvic pouch failure. Dis Colon Rectum 1997 40 : 257 62.
32. Swenson BR, Hollenbeak CS, Koltun WA. Hospital costs and risk factors associated with complications of the ileal pouch anal anastomosis. Surgery 2002 132 : 767 73 discussion 773-4.
33. Tulchinsky H, Hawley PR, Nicholls J. Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg 2003 238 : 229 34.
34. Gregor JC, McDonald JWD, Klar N. An evaluation of the utility measurement in Crohn's disease. Inflamm Bowel Dis 1997 3 : 265 76.
35. Arseneau KO, Sultan S, Provenzale DT, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol 2006 4 : 1135 42.
36. Kennedy ED, Detsky AS, Llewellyn-Thomas HA, et al. Can the standard gamble be used to determine utilities for uncertain health states? An example using postoperative maintenance therapy in Crohn's disease. Med Decis Making 2000 20 : 72 8.
37. McLeod RS, Churchill DN, Lock AM, et al. Quality of life of patients with ulcerative colitis preoperatively and postoperatively. Gastroenterology 1991 101 : 1307 13.
38. Muir AJ, Edwards LJ, Sanders LL, et al. A prospective evaluation of health-related quality of life after ileal pouch anal anastomosis for ulcerative colitis. Am J Gastroenterol 2001 96 : 1480 5.
39. 2005 Redbook: Pharmacy's fundamental reference (Red Book drug topics). Fleming T, ed. Montvale, NJ : Thomson Healthcare, 2005.
40. Ollendorf DA, Lidsky L. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting. Am J Ther 2006 13 : 502 6.
41. Physician Fee Schedule. Available at : http://www.cms.hhs.gov/ PhysicianFeeSched/ Accessed July 28, 2008.
42. The DRG handbook: Comparative clinical and financial standards. Baltimore, MD : Health Care Investment Analyst, Inc., Ernst and Young, 2004.
43. Briggs A, Claxton K, Sculpher M. Making decision models probabilistic. In : Decision modelling for health economic evaluation. Cambridge, MA : Oxford University Press, 2006 77 120.
44. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: A systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005 100 : 1345 53.
45. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol 2002 35 : 151 6.
46. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007 132 : 66 75 quiz 432-3.
47. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007 5 : 95 102.
48. Lichtenstein GR, Kamm MA, Sandborn WJ, et al. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: Efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther 2008 27 : 1094 102.
49. Provenzale D, Shearin M, Phillips-Bute BG, et al. Health-related quality of life after ileoanal pull-through evaluation and assessment of new health status measures. Gastroenterology 1997 113 : 7 14.